EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer

@inproceedings{Semmlinger2018EP3E,
  title={EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer},
  author={Anna Semmlinger and Viktoria von Schoenfeldt and Verena Wolf and Alexandra Meuter and Theresa Maria Kolben and Thomas Kolben and Christine Zeder-Goess and Florian C. Weis and Julia Gallwas and Rachel Wuerstlein and Kerstin Hermelink and Elisa Schmoeckel and Nadia Harbeck and Doris Mayr and Sven Mahner and Udo Jeschke and Nina Ditsch},
  booktitle={BMC Cancer},
  year={2018}
}
In various cancers, overexpression of cyclooxygenase (COX)-2 and elevated prostaglandin (PG) E2 synthesis have been associated with tumor development and progression. The potential of COX-2 inhibitors in cancer prevention and treatment has been shown repeatedly; however, their clinical use is limited due to toxicity. PGE2 signals via EP receptors 1–4, whose functions are analyzed in current research in search for targeted anti-PG therapies. EP2 and EP4 rather promote tumorigenesis, while the… CONTINUE READING
BETA

References

Publications referenced by this paper.
SHOWING 1-10 OF 34 REFERENCES

Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer

A Ristimaki, A Sivula, +5 authors J. Isola
  • Cancer Res
  • 2002
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

12538–45

Zent R Carmosino M Breyer MD Breyer RM Pozzi A. Mouse E Macias-Perez IM, gamma receptor variants reduce tumor cell proliferation, tumorigenesis in vivo. J Biol Chem. 2008, 28318
  • • We accept pre-submission inquiries • Our selector tool helps you to find the most relevant journal • We provide round the clock customer support • Convenient online submission • Thorough peer review • Inclusion in PubMed and all major indexing services • Maximum visibility for your research Submi
  • 2018
VIEW 1 EXCERPT

possible therapeutic targets? Br J Pharmacol

G O'Callaghan, E2 HoustonA.Prostaglandin, the EP receptors in malignancy
  • 2015;172(22): 5239–50. Semmlinger et al. BMC Cancer
  • 2018
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…